Market Cap 234.04M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,080,000
Avg Vol 2,179,004
Day's Range N/A - N/A
Shares Out 41.57M
Stochastic %K 71%
Beta 0.47
Analysts Strong Sell
Price Target $16.60

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
BinaryLogic
BinaryLogic Oct. 25 at 12:54 PM
$IMRX [Stochastics] If you look at the 3YR Weekly chart, you will see that the SP pulled back inline with the 200DMA, RSI is back to a reasonable level, still with Bullish overall momentum. $6.0 is a consistent support/resistance line, and you can see that on the 1YR Daily. If/where the stock re-establishes this as support, look for a material upward continuation (IMO). Again-the Company just secured $200M in equity between Public/Private placement at $9.23. This fortifies the balance sheet, while continuing high-potential product pipeline. 50-100% upside, as I noted last week.
0 · Reply
AlbinoFace
AlbinoFace Oct. 24 at 6:40 PM
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 24 at 6:22 PM
0 · Reply
tgewaz1
tgewaz1 Oct. 24 at 4:39 PM
$IMRX Nice climb
0 · Reply
Gamer001
Gamer001 Oct. 24 at 4:38 PM
$IMRX $9 in horizon👏
0 · Reply
bioland
bioland Oct. 24 at 4:20 PM
$IMRX Finally...
0 · Reply
OptimistJP
OptimistJP Oct. 24 at 1:33 PM
$IMRX I can never really make sense of the market, so why would the underwriters exercise their option to purchase up to an additional 2,843,987 shares (as noted in the September 25, 2025, public offering announcement) at the offering price of $9.23 when they could easily purchase those shares on the open market as considerably less? No rush, right?
1 · Reply
BinaryLogic
BinaryLogic Oct. 24 at 11:19 AM
$IMRX The SP has retraced to the 100DMA following which time I estimate a consolidation period near term. MACD crossover, then move materially higher. 50-100% upside from this level (IMO) possible on broader positive market sentiment and continued strong test results. Recall-the latest Public/Private placement was completed at a $9.23 strike, securing the Company nearly $200M to support operations. The stock is now trading at/around $5.5-5.7.
0 · Reply
SpittingImage
SpittingImage Oct. 24 at 3:30 AM
$IMRX volume is slowing but thays a good thing for this stock.
0 · Reply
bioland
bioland Oct. 24 at 3:03 AM
0 · Reply
Latest News on IMRX
Immuneering Corporation - Special Call

Sep 29, 2025, 4:37 PM EDT - 25 days ago

Immuneering Corporation - Special Call


Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 16, 2025, 7:00 AM EDT - 5 weeks ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board


Immuneering Announces Closing of $25 Million Private Placement

Aug 26, 2025, 4:05 PM EDT - 2 months ago

Immuneering Announces Closing of $25 Million Private Placement


Immuneering Announces $25 Million Private Placement

Aug 21, 2025, 8:00 AM EDT - 2 months ago

Immuneering Announces $25 Million Private Placement


Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 7 months ago

Immuneering Corporation Announces Grant of Inducement Award


Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer


Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 10 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?


Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 11 months ago

Immuneering Launches Pancreatic Cancer Advisory Board


Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month


Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.


BinaryLogic
BinaryLogic Oct. 25 at 12:54 PM
$IMRX [Stochastics] If you look at the 3YR Weekly chart, you will see that the SP pulled back inline with the 200DMA, RSI is back to a reasonable level, still with Bullish overall momentum. $6.0 is a consistent support/resistance line, and you can see that on the 1YR Daily. If/where the stock re-establishes this as support, look for a material upward continuation (IMO). Again-the Company just secured $200M in equity between Public/Private placement at $9.23. This fortifies the balance sheet, while continuing high-potential product pipeline. 50-100% upside, as I noted last week.
0 · Reply
AlbinoFace
AlbinoFace Oct. 24 at 6:40 PM
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 24 at 6:22 PM
0 · Reply
tgewaz1
tgewaz1 Oct. 24 at 4:39 PM
$IMRX Nice climb
0 · Reply
Gamer001
Gamer001 Oct. 24 at 4:38 PM
$IMRX $9 in horizon👏
0 · Reply
bioland
bioland Oct. 24 at 4:20 PM
$IMRX Finally...
0 · Reply
OptimistJP
OptimistJP Oct. 24 at 1:33 PM
$IMRX I can never really make sense of the market, so why would the underwriters exercise their option to purchase up to an additional 2,843,987 shares (as noted in the September 25, 2025, public offering announcement) at the offering price of $9.23 when they could easily purchase those shares on the open market as considerably less? No rush, right?
1 · Reply
BinaryLogic
BinaryLogic Oct. 24 at 11:19 AM
$IMRX The SP has retraced to the 100DMA following which time I estimate a consolidation period near term. MACD crossover, then move materially higher. 50-100% upside from this level (IMO) possible on broader positive market sentiment and continued strong test results. Recall-the latest Public/Private placement was completed at a $9.23 strike, securing the Company nearly $200M to support operations. The stock is now trading at/around $5.5-5.7.
0 · Reply
SpittingImage
SpittingImage Oct. 24 at 3:30 AM
$IMRX volume is slowing but thays a good thing for this stock.
0 · Reply
bioland
bioland Oct. 24 at 3:03 AM
0 · Reply
putsandcalls
putsandcalls Oct. 23 at 4:51 PM
$IMRX fwiw and im sure its nothing but nov call premiums ha ve moved up here.
1 · Reply
LabPsycho
LabPsycho Oct. 23 at 1:41 PM
$TNGX My guess is this is going to mirror the collapse 50% retrace of $IMRX after it went from ~ 1 to 10 then did an offering.
1 · Reply
CantNameThatTune
CantNameThatTune Oct. 23 at 9:38 AM
$IMRX Not enough poops floating around for it to matter. But the 9 mo results came late while the company organized the financing. That won't be the case this time. Company has met with FDA and these results will come sooner so you get dbl news of great 12 month survival followed immediately by an IND submitted and gladly accepted by The FDA.
0 · Reply
CantNameThatTune
CantNameThatTune Oct. 23 at 9:23 AM
$IMRX All u need to know as these one year survival ratesare coming at any time. If you were around earlier back ib Jul-Aug, which none of you were, the stock moved $1-$10 in advance of the 9 month results. https://www.biospace.com/drug-development/immuneering-asset-nearly-doubles-overall-survival-in-pancreatic-cancer-after-9-months
1 · Reply
Prosperity1_
Prosperity1_ Oct. 23 at 3:27 AM
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 23 at 12:24 AM
$TNXP $IMRX $NUVB $CCCC $ALT five cheap biotechs worth holding long 💪
0 · Reply
bet_on_biotechs
bet_on_biotechs Oct. 22 at 11:55 PM
$IMRX The key question arises: Where is an investor likely to have a better chance of making money – with $RVMD or $IMRX? In the long term, there is absolutely no news about RVMD that could lead to a doubling of the SP. This is based on the lack of logic behind the scenario of simply multiplying an existing MCAP of $10 billion by $20 billion. Neither an assumed FDA approval nor initial product sales potentially received by RVMD will achieve this. From now on, the performance for speculators would no longer be satisfactory. Any significantly undervalued stock is likely to deliver better – and faster – performance. Let's compare IMRX – here, every positive news item likely brings with it the chance of topping RVMD's future annual performance. Simple theory – but one that will prove true.
0 · Reply
OptimistJP
OptimistJP Oct. 22 at 11:39 PM
$IMRX Watching $BYND today just made me think "what if". What if the Reddit group would target $IMRX? $BYND traded over 2 billion shares today and ran from $0.56 on Monday to over $7 today, including the trading of over 500 million shares even before the opening today. Imagine what the share price of $IMRX would be if we had a day with over 2 billion shares traded.
0 · Reply
bioland
bioland Oct. 22 at 4:35 PM
$IMRX Another 100K went short to keep it here...while they scoop it up with the other hand. Very obvious game here now...
1 · Reply
edward103
edward103 Oct. 22 at 2:31 PM
$IMRX I’m not adding to the FUD, I am only stating what should now be obvious. See for years they thought RAS could not be targeted. So IMRX went after MEK and it shows promise. But RVMD changed the game (for now). They showed you can indeed target RAS and successfully. As it’s prominent in PDAC (same space as IMRX) its starting to seem that IMRX is too late to the party i.e., RAS targeted therapy is the future NOT MEK. All the data is not in. But IF IMRX shows ~ 12mOS (great) that would still be least than RVMD in monotherapy. If someone was told they could take a pill and NO chemo what do you think they’ll opt for? So that is why IMRX us getting hit.
5 · Reply
SylvanEmperor
SylvanEmperor Oct. 22 at 2:24 PM
$IMRX yeah... Oversold now it seems.
0 · Reply
velle
velle Oct. 22 at 2:21 PM
$IMRX Ouch So much for the slow grind up above six
0 · Reply